Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Iovance Biotherapeutics (IOVA) over the last 9 years, with Q3 2025 value amounting to $9.9 million.

  • Iovance Biotherapeutics' Treasury Shares fell 31.45% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 31.45%. This contributed to the annual value of $9.5 million for FY2024, which is 17643.07% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Treasury Shares is $9.9 million, which was down 31.45% from $11.4 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Treasury Shares peaked at $12.2 million during Q1 2025, and registered a low of $3.5 million during Q4 2023.
  • For the 3-year period, Iovance Biotherapeutics' Treasury Shares averaged around $8.4 million, with its median value being $9.9 million (2025).
  • Its Treasury Shares has fluctuated over the past 5 years, first skyrocketed by 20893.41% in 2024, then plummeted by 360.33% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Treasury Shares (Quarter) stood at $3.5 million in 2023, then skyrocketed by 176.43% to $9.5 million in 2024, then rose by 3.53% to $9.9 million in 2025.
  • Its Treasury Shares was $9.9 million in Q3 2025, compared to $11.4 million in Q2 2025 and $12.2 million in Q1 2025.